99 related articles for article (PubMed ID: 12134168)
1. Hybrid insulin cocrystals for controlled release delivery.
Brader ML; Sukumar M; Pekar AH; McClellan DS; Chance RE; Flora DB; Cox AL; Irwin L; Myers SR
Nat Biotechnol; 2002 Aug; 20(8):800-4. PubMed ID: 12134168
[TBL] [Abstract][Full Text] [Related]
2. A crystal clear solution for insulin delivery.
Merkle HP; Jen A
Nat Biotechnol; 2002 Aug; 20(8):789-90. PubMed ID: 12148005
[No Abstract] [Full Text] [Related]
3. Sustained release of insulin through skin by intradermal microdelivery system.
Wu Y; Gao Y; Qin G; Zhang S; Qiu Y; Li F; Xu B
Biomed Microdevices; 2010 Aug; 12(4):665-71. PubMed ID: 20306299
[TBL] [Abstract][Full Text] [Related]
4. Preparation and characterization of a cocrystalline suspension of [LysB28,ProB29]-human insulin analogue.
DeFelippis MR; Bakaysa DL; Bell MA; Heady MA; Li S; Pye S; Youngman KM; Radziuk J; Frank BH
J Pharm Sci; 1998 Feb; 87(2):170-6. PubMed ID: 9519149
[TBL] [Abstract][Full Text] [Related]
5. [A study of the absorption of NPH insulin administered into subcutaneous tissue: in vitro study of the mechanism of insulin release from NPH insulin crystal].
Yanagisawa K
Hokkaido Igaku Zasshi; 1992 Jan; 67(1):81-8. PubMed ID: 1559663
[TBL] [Abstract][Full Text] [Related]
6. Clinical strategies for controlling peaks and valleys: type 1 diabetes.
Bolli GB
Int J Clin Pract Suppl; 2002 Jul; (129):65-74. PubMed ID: 12166610
[TBL] [Abstract][Full Text] [Related]
7. pI-shifted insulin analogs with extended in vivo time action and favorable receptor selectivity.
Kohn WD; Micanovic R; Myers SL; Vick AM; Kahl SD; Zhang L; Strifler BA; Li S; Shang J; Beals JM; Mayer JP; DiMarchi RD
Peptides; 2007 Apr; 28(4):935-48. PubMed ID: 17328992
[TBL] [Abstract][Full Text] [Related]
8. Parental preference of prandial insulin aspart compared with preprandial human insulin in a basal-bolus scheme with NPH insulin in a 12-wk crossover study of preschool children with type 1 diabetes.
Danne T; Råstam J; Odendahl R; Näke A; Schimmel U; Szczepanski R; Moeller J; Deiss D
Pediatr Diabetes; 2007 Oct; 8(5):278-85. PubMed ID: 17850471
[TBL] [Abstract][Full Text] [Related]
9. Structural characterization of insulin NPH formulations.
Norrman M; Hubálek F; Schluckebier G
Eur J Pharm Sci; 2007 Apr; 30(5):414-23. PubMed ID: 17339105
[TBL] [Abstract][Full Text] [Related]
10. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogs versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes.
Hassan K; Rodriguez LM; Johnson SE; Tadlock S; Heptulla RA
Pediatrics; 2008 Mar; 121(3):e466-72. PubMed ID: 18299307
[TBL] [Abstract][Full Text] [Related]
11. Insulin glargine: a new once-daily basal insulin for the management of type 1 and type 2 diabetes mellitus.
Lam S
Heart Dis; 2003; 5(3):231-40. PubMed ID: 12783637
[TBL] [Abstract][Full Text] [Related]
12. Mesoporous silica nanoparticle-based double drug delivery system for glucose-responsive controlled release of insulin and cyclic AMP.
Zhao Y; Trewyn BG; Slowing II; Lin VS
J Am Chem Soc; 2009 Jun; 131(24):8398-400. PubMed ID: 19476380
[TBL] [Abstract][Full Text] [Related]
13. Insulin microcrystal suspension as a long-acting formulation for pulmonary delivery.
Kwon JH; Lee BH; Lee JJ; Kim CW
Eur J Pharm Sci; 2004 Jun; 22(2-3):107-16. PubMed ID: 15158896
[TBL] [Abstract][Full Text] [Related]
14. Proportional dose-response relationship and lower within-patient variability of insulin detemir and NPH insulin in subjects with type 1 diabetes mellitus.
Wutte A; Plank J; Bodenlenz M; Magnes C; Regittnig W; Sinner F; Rønn B; Zdravkovic M; Pieber TR
Exp Clin Endocrinol Diabetes; 2007 Jul; 115(7):461-7. PubMed ID: 17647145
[TBL] [Abstract][Full Text] [Related]
15. Insulin glargine (Lantus).
Owens DR; Griffiths S
Int J Clin Pract; 2002; 56(6):460-6. PubMed ID: 12166545
[TBL] [Abstract][Full Text] [Related]
16. Influence of microencapsulation method and peptide loading on formulation of poly(lactide-co-glycolide) insulin nanoparticles.
Kumar PS; Ramakrishna S; Saini TR; Diwan PV
Pharmazie; 2006 Jul; 61(7):613-7. PubMed ID: 16889069
[TBL] [Abstract][Full Text] [Related]
17. Optimization and in vivo evaluation of an oral dual controlled-release tablet dosage form of insulin and duck ovomucoid.
Agarwal V; Nazzal S; Khan MA
Pharm Dev Technol; 2008; 13(4):291-8. PubMed ID: 18618331
[TBL] [Abstract][Full Text] [Related]
18. Insulin glargine: long-acting basal insulin analog for improved metabolic control.
Gerich JE
Curr Med Res Opin; 2004 Jan; 20(1):31-7. PubMed ID: 14741069
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic and pharmacodynamic advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety.
Rolla A
Am J Med; 2008 Jun; 121(6 Suppl):S9-S19. PubMed ID: 18514090
[TBL] [Abstract][Full Text] [Related]
20. Reversible pegylation of insulin facilitates its prolonged action in vivo.
Shechter Y; Mironchik M; Rubinraut S; Tsubery H; Sasson K; Marcus Y; Fridkin M
Eur J Pharm Biopharm; 2008 Sep; 70(1):19-28. PubMed ID: 18495444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
